A Phase 2 interventional study of Selgantolimod and Placebo in Hepatitis B and HIV Infections, sponsored by National Institute of Allergy and Infectious Diseases (NIAID). Terminated at 12 sites in 4 countries. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-11-17.
Sponsored by National Institute of Allergy and Infectious Diseases (NIAID) · Phase 2, Interventional, and Treatment
ACTG Network funding disruptions
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 15 studies in Hepatitis B by National Institute of Allergy and Infectious Diseases (NIAID) — none open to participants now, none under way, none of them phase 3. Hepatitis B · National Institute of Allergy and Infectious Diseases (NIAID).
Among the 15 studies in Hepatitis B by National Institute of Allergy and Infectious Diseases (NIAID), this one is the 9th largest by enrollment of the 13 interventional ones that give a count, is the only one that started in 2023, is one of 6 in phase 2, and was the 15th registered.
1,048 studies on the registry are indexed under Hepatitis B; 141 are open to participants now.
Browse Hepatitis B studies →None of the 15 studies in Hepatitis B by National Institute of Allergy and Infectious Diseases (NIAID) is open now. The open studies under Hepatitis B, anywhere →
Of the 80 Hepatitis B studies recruiting now, 40 (50%) set no upper age limit and 35 (44%) stop at 75 or younger; 14 take children under 18; 20 take healthy volunteers.
This study: 18 Years to 70 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
15 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 8 · Phase 3 2
First in 1999; this study’s year is marked. 1 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 29 is below the median of 145 across 758 interventional studies indexed under Hepatitis B.
Median enrollment 30 across the 13 interventional studies, 3,158 across the 2 observational. Of the 12 that completed or were terminated, 2 (17%) have results posted.
This tab as a report to print or save as PDF → With an account.
National Institute of Allergy and Infectious Diseases (NIAID) is the lead sponsor of 2,449 studies on the registry; 181 are open to participants now.
Of its 406 completed or terminated interventional studies of FDA-regulated products, 303 (75%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 15 studies in Hepatitis B by National Institute of Allergy and Infectious Diseases (NIAID), from their registry updates:
This tab as a report to print or save as PDF → With an account.
The study aimed to assess safety and tolerability of oral toll-like receptor (TLR) 8 agonist Selgantolimod (SLGN) administered for 24 weeks in participants with both chronic hepatitis B (CHB) and HIV who had received suppressive antiviral therapy for both viruses for ≥5 years and have qHBsAg level >1000 (3 log10) IU/mL at screening. The study also evaluated if TLR8 stimulation with SLGN will reduce hepatitis B surface antigen (HBsAg) titers in the blood.
The primary hypotheses of this study were:
A5394 was a phase II, randomized, double-blind, placebo-controlled clinical trial to assess the safety, tolerability, and efficacy of 24 weeks of treatment with SLGN. Participants were randomized in a 3:1 ratio to receive SLGN or its placebo, and randomization was stratified by HBeAg status. Participants were planned to be on study for up to 48 weeks (24-week treatment phase and 24-week post-treatment follow-up). All participants were required to remain on their non-study-provided antiviral therapy throughout the study.
The primary efficacy analysis was planned to be conducted as a single-arm study of the SLGN study arm.
Accrual was terminated early and did not reach the target sample size of 48 due to ACTG Network funding disruptions.
The criteria were revised on the registry on Nov 17, 2026. See what changed
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CD4 count
The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received Selgantolimod 3 mg (two 1.5 mg tablets) once weekly for 24 weeks.
Drug: Selgantolimod
Participants received matching Placebo for Selgantolimod once weekly for 24 weeks.
Drug: Placebo
Two 1.5 mg tablets taken orally once a week
Also known as: SLGN
Two matching placebo tablets taken orally once a week
Proportion of Participants Who Experienced Grade ≥2 Adverse Events (AEs) in Arm A
An adverse event (AE) is any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or diagnosis that occurs in a study participant during the conduct of the study REGARDLESS of the attribution. This includes any occurrence that is new in onset or aggravated in severity or frequency from the baseline condition. All AEs that are reported must have their severity graded. Adverse events were graded according to the Division of AIDS Table for Grading the Severity of Adult and Pediatric Adverse Events (DAIDS AE Grading Table), corrected Version 2.1, July 2017. Adverse events were graded on a scale from 1-5: 1=mild, 2=moderate, 3=severe, 4=life-threatening, 5=death. Higher scores/grades mean a worse outcome. The proportion of participants with Grade 2 or higher adverse events was calculated, along with a two-sided 95% confidence interval constructed using the Clopper-Pearson exact method for binomial data.
Time frame: From study treatment initiation through Week 24
Proportion of Participants Who Prematurely Discontinued Treatment Due to Adverse Events (AEs) in Arm A
The proportion of participants who had premature discontinuation of Selgantolimod due to adverse event(s) was calculated, along with a two-sided 95% confidence interval constructed using the Clopper-Pearson exact method for binomial data.
Time frame: From study treatment initiation through Week 24
Proportion of Participants With ≥1 log10 IU/mL Decline From Baseline in Quantitative HBsAg (qHBsAg) After SLGN Treatment at Week 24
The proportion of participants who experienced ≥1 log10 IU/mL decline in quantitative HBsAg at Week 24 was calculated, along with a two-sided 90% confidence interval constructed using the Clopper-Pearson exact method for binomial data.
Time frame: Week 24
Proportion of Participants With ≥1 log10 IU/mL Decline From Baseline in qHBsAg at Any Time During the Study After SLGN Treatment Initiation
The proportion of participants who experienced ≥1 log10 IU/mL decline in quantitative HBsAg at any time during the study after SLGN treatment initiation will be calculated, along with a two-sided 90% confidence interval constructed using the Clopper-Pearson exact method for binomial data.
Time frame: From Baseline (Entry) through Week 48
Proportion of Participants With ≥0.5 log10 IU/mL Decline From Baseline in qHBsAg After SLGN Treatment at Week 24
The proportion of participants who experienced ≥0.5 log10 IU/mL decline in quantitative HBsAg at Week 24 was calculated, along with a two-sided 90% confidence interval constructed using the Clopper-Pearson exact method for binomial data.
Time frame: Week 24
Proportion of Participants With ≥0.5 log10 IU/mL Decline in qHBsAg From Baseline at Any Time During the Study After SLGN Treatment Initiation
The proportion of participants who experienced ≥0.5 log10 IU/mL decline in quantitative HBsAg at any time during the study after SLGN treatment initiation will be calculated, along with a two-sided 90% confidence interval constructed using the Clopper-Pearson exact method for binomial data.
Time frame: From Baseline (Entry) through Week 48
Proportion of Participants Who Achieve HBsAg Loss After SLGN Initiation and Who Sustain HBsAg Loss During Follow-up
Sustained HBsAg loss is defined as HBsAg converting from positive to negative after initiation of SLGN, without any subsequent positive HBsAg result. The proportion of participants who achieved HBsAg loss after SLGN initiation and who sustained HBsAg loss during follow-up will be calculated, along with a two-sided 90% confidence interval constructed using the Clopper-Pearson exact method for binomial data.
Time frame: From Baseline (Entry) through Week 48
Changes From Baseline in qHBsAg Levels
The absolute change in qHBsAg level refers to the value at the follow-up time point minus the value at Baseline (Entry).
Time frame: Baseline (Entry) and Weeks 4, 12, 24, 36 and 48
Proportion of Hepatitis B E-antigen (HBeAg) Positive Participants at Baseline Who Lose HBeAg at Any Time During the Study
HBeAg loss is defined as HBeAg changing from positive to negative. The proportion of participants who lose HBeAg at any time during the study will be calculated, along with a two-sided 90% confidence interval constructed using the Clopper-Pearson exact method for binomial data.
Time frame: From Baseline (Entry) through Week 48
Proportion of Hepatitis B E-antibody (Anti-HBe) Negative Participants at Baseline Who Develop Anti-HBe at Any Time During the Study
Developing anti-HBe, or anti-HBe gain, is defined as HBeAb changing from negative to positive. The proportion of participants who develop HBeAb at any time during the study will be calculated, along with a two-sided 90% confidence interval constructed using the Clopper-Pearson exact method for binomial data.
Time frame: From Baseline (Entry) through Week 48
Proportion of Hepatitis B Surface Antibody (Anti-HBs) Negative Participants at Baseline Who Develop Anti-HBs at Any Time During the Study
Developing anti-HBs, or anti-HBs gain, is defined as HBsAb changing from negative to positive. The proportion of participants who develop HBsAb at any time during the study will be calculated, along with a two-sided 90% confidence interval constructed using the Clopper-Pearson exact method for binomial data.
Time frame: From Baseline (Entry) through Week 48
Number of Participants With Plasma HIV RNA >50 Copies/mL
The number of participants with detectable plasma HIV RNA \>50 copies/mL will be reported.
Time frame: Weeks 2, 4, 24 and 48
Number of Participants With Serum HBV DNA >50 IU/mL
The number of participants with detectable serum HBV DNA \>50 copies/mL will be reported.
Time frame: Weeks 2, 4, 24 and 48
Participants enrolled during the recruitment period of May 2023 to May 2025 from 12 sites based in the United States, Thailand, Peru, and Brazil.
| Milestone | Arm A | Arm B |
|---|---|---|
| Started | 22 | 7 |
| Completed | 20 | 7 |
| Not completed | 2 | 0 |
| Withdrew: Withdrawal by subject | 2 | 0 |
An adverse event (AE) is any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or diagnosis that occurs in a study participant during the conduct of the study REGARDLESS of the attribution. This includes any occurrence that is new in onset or aggravated in severity or frequency from the baseline condition. All AEs that are reported must have their severity graded. Adverse events were graded according to the Division of AIDS Table for Grading the Severity of Adult and Pediatric Adverse Events (DAIDS AE Grading Table), corrected Version 2.1, July 2017. Adverse events were graded on a scale from 1-5: 1=mild, 2=moderate, 3=severe, 4=life-threatening, 5=death. Higher scores/grades mean a worse outcome. The proportion of participants with Grade 2 or higher adverse events was calculated, along with a two-sided 95% confidence interval constructed using the Clopper-Pearson exact method for binomial data.
| proportion of participants | Arm A |
|---|---|
| Proportion of Participants Who Experienced Grade ≥2 Adverse Events (AEs) in Arm A | 0.727 (0.498 to 0.893) |
The proportion of participants who had premature discontinuation of Selgantolimod due to adverse event(s) was calculated, along with a two-sided 95% confidence interval constructed using the Clopper-Pearson exact method for binomial data.
| proportion of participants | Arm A |
|---|---|
| Proportion of Participants Who Prematurely Discontinued Treatment Due to Adverse Events (AEs) in Arm A | 0.045 (0.001 to 0.228) |
The proportion of participants who experienced ≥1 log10 IU/mL decline in quantitative HBsAg at Week 24 was calculated, along with a two-sided 90% confidence interval constructed using the Clopper-Pearson exact method for binomial data.
| proportion of participants | Arm A |
|---|---|
| Proportion of Participants With ≥1 log10 IU/mL Decline From Baseline in Quantitative HBsAg (qHBsAg) After SLGN Treatment at Week 24 | 0.050 (0.003 to 0.216) |
The proportion of participants who experienced ≥1 log10 IU/mL decline in quantitative HBsAg at any time during the study after SLGN treatment initiation will be calculated, along with a two-sided 90% confidence interval constructed using the Clopper-Pearson exact method for binomial data.
Results for this outcome have not been posted.
The proportion of participants who experienced ≥0.5 log10 IU/mL decline in quantitative HBsAg at Week 24 was calculated, along with a two-sided 90% confidence interval constructed using the Clopper-Pearson exact method for binomial data.
| proportion of participants | Arm A |
|---|---|
| Proportion of Participants With ≥0.5 log10 IU/mL Decline From Baseline in qHBsAg After SLGN Treatment at Week 24 | 0.050 (0.003 to 0.216) |
The proportion of participants who experienced ≥0.5 log10 IU/mL decline in quantitative HBsAg at any time during the study after SLGN treatment initiation will be calculated, along with a two-sided 90% confidence interval constructed using the Clopper-Pearson exact method for binomial data.
Results for this outcome have not been posted.
Sustained HBsAg loss is defined as HBsAg converting from positive to negative after initiation of SLGN, without any subsequent positive HBsAg result. The proportion of participants who achieved HBsAg loss after SLGN initiation and who sustained HBsAg loss during follow-up will be calculated, along with a two-sided 90% confidence interval constructed using the Clopper-Pearson exact method for binomial data.
Results for this outcome have not been posted.
The absolute change in qHBsAg level refers to the value at the follow-up time point minus the value at Baseline (Entry).
Results for this outcome have not been posted.
HBeAg loss is defined as HBeAg changing from positive to negative. The proportion of participants who lose HBeAg at any time during the study will be calculated, along with a two-sided 90% confidence interval constructed using the Clopper-Pearson exact method for binomial data.
Results for this outcome have not been posted.
Developing anti-HBe, or anti-HBe gain, is defined as HBeAb changing from negative to positive. The proportion of participants who develop HBeAb at any time during the study will be calculated, along with a two-sided 90% confidence interval constructed using the Clopper-Pearson exact method for binomial data.
Results for this outcome have not been posted.
Developing anti-HBs, or anti-HBs gain, is defined as HBsAb changing from negative to positive. The proportion of participants who develop HBsAb at any time during the study will be calculated, along with a two-sided 90% confidence interval constructed using the Clopper-Pearson exact method for binomial data.
Results for this outcome have not been posted.
The number of participants with detectable plasma HIV RNA \>50 copies/mL will be reported.
Results for this outcome have not been posted.
The number of participants with detectable serum HBV DNA \>50 copies/mL will be reported.
Results for this outcome have not been posted.
Collected over From study entry to study completion at Week 48, or premature study discontinuation. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Arm A | 0/22 (0%) | 3/22 (13.6%) | 16/22 (72.7%) |
| Arm B | 0/7 (0%) | 0/7 (0%) | 7/7 (100%) |
| Event | Arm A | Arm B |
|---|---|---|
| Pancreatitis acuteGastrointestinal disorders | 1/22 | 0/7 |
| Squamous cell carcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/22 | 0/7 |
| Transient ischaemic attackNervous system disorders | 1/22 | 0/7 |
| Event | Arm A | Arm B |
|---|---|---|
| Creatinine renal clearance decreasedInvestigations | 4/22 | 3/7 |
| DiarrhoeaGastrointestinal disorders | 1/22 | 2/7 |
| NauseaGastrointestinal disorders | 5/22 | 0/7 |
| DyspepsiaGastrointestinal disorders | 0/22 | 1/7 |
| GastritisGastrointestinal disorders | 0/22 | 1/7 |
| InfluenzaInfections and infestations | 0/22 | 1/7 |
| Parasitic gastroenteritisInfections and infestations | 0/22 | 1/7 |
| Respiratory tract infection viralInfections and infestations | 0/22 | 1/7 |
| Foot fractureInjury, poisoning and procedural complications | 0/22 | 1/7 |
| Blood pressure increasedInvestigations | 0/22 | 1/7 |
| Age, Continuous(years) | Arm A | Arm B | Total |
|---|---|---|---|
| Median | 48 (42 to 55) | 43 (40 to 53) | 46 (42 to 54) |
| Age, Customized(Participants) | Arm A | Arm B | Total |
|---|---|---|---|
| 30-39 years | 5 | 1 | 6 |
| 40-49 years | 6 | 3 | 9 |
| 50-65 years | 11 | 3 | 14 |
| Sex: Female, Male(Participants) | Arm A | Arm B | Total |
|---|---|---|---|
| Female | 2 | 1 | 3 |
| Male | 20 | 6 | 26 |
| Ethnicity (NIH/OMB)(Participants) | Arm A | Arm B | Total |
|---|---|---|---|
| Hispanic or Latino | 3 | 1 | 4 |
| Not Hispanic or Latino | 19 | 6 | 25 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Race/Ethnicity, Customized(Participants) | Arm A | Arm B | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 12 | 4 | 16 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 4 | 2 | 6 |
| White | 4 | 1 | 5 |
| Other | 1 | 0 | 1 |
| More than one race | 0 | 0 | 0 |
| Unknown | 1 | 0 | 1 |
| Region of Enrollment(participants) | Arm A | Arm B | Total |
|---|---|---|---|
| United States | 6 | 2 | 8 |
| Brazil | 3 | 2 | 5 |
| Thailand | 12 | 3 | 15 |
| Peru | 1 | 0 | 1 |
| Hepatitis B DNA(Participants) | Arm A | Arm B | Total |
|---|---|---|---|
| <10 IU/mL | 19 | 7 | 26 |
| 50+ IU/mL | 3 | 0 | 3 |
| Hepatitis B Virus Surface Antigen(IU/mL) | Arm A | Arm B | Total |
|---|---|---|---|
| Median | 1663 (1057 to 4169) | 1885 (1099 to 3620) | 1776 (1099 to 3620) |
8 further baseline measures are reported on the registry.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Individual participant data that underlie results in the publication, after deidentification
Supporting information: Study protocol, Statistical analysis plan
Time frame: Beginning 3 months following publication and available throughout period of funding of the Advancing Clinical Therapeutics Globally (ACTG) by NIH
Access criteria: With whom? Researchers who provide a methodologically sound proposal for use of the data that is approved by the ACTG. For what types of analyses? To achieve aims in the proposal approved by the ACTG. By what mechanism will data be made available? Researchers may submit a request for access to data using the ACTG "Data Request" form at: https://actgnetwork.org/submit-a-proposal/. Researchers of approved proposals will need to sign an ACTG Data Use Agreement before receiving the data.
Ran from May 2023 to primary completion in Oct 2025, 29 months.
Results were first posted in Nov 2026, 1 year after primary completion.
How these figures are worked out, and which studies are left out of them.
ACTG Network funding disruptions
ACTG Network funding disruptions
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is terminated, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Selgantolimod
National Institute of Allergy and Infectious Diseases (NIAID) →